바이오파마 업계 전망(-2040년)

Adoption of Artificial Intelligence Is Driving Transformational Growth Across the Biopharma Value Chain

The biopharma industry has been evolving over the past few decades. This study analyses the top ten trends that will impact the future of the biopharma industry through 2040.

The future of biopharma will be driven by innovation in AI and ML, particularly generative AI, and by advancements in translational medicine and synthetic biology. Future clinical development of biologics will focus on personalized medicine and will leverage more decentralized clinical trials in the drug development process. In biologics manufacturing, novel approaches and advancements in drug delivery will transform how medications are administered. This will improve therapeutic outcomes in drug delivery and transform the way medications are administered, thereby improving therapeutic outcomes.

Sustainability in manufacturing and supply chain will become more important as companies increasingly focus on reducing their environmental footprint by adopting green practices and sustainably sourcing raw materials.

On the commercial side, new age technologies (such as digital therapeutics and drone delivery) will play an increasingly greater role. In terms of biopharma market expansion, emerging markets will gain importance - especially China, which will become an important region for biopharma R&D to commercialization in the coming years. The biopharma regulatory landscape will continue to evolve to keep pace with scientific advancements, while agencies such as the US FDA and EMA will collaborate more with biopharmaceutical companies to ensure patients have timely access to life-saving therapies. Value-based reimbursement will gain greater prominence in the coming years for biologics in major markets.

Big tech will revolutionize drug discovery through AI-driven platforms for protein prediction, molecular screening, and target identification. Cloud-native simulations and emerging quantum computing will accelerate preclinical timelines, while R&D-as-a-service models will give biopharma access to these tools without heavy in-house investment.

Table of Contents

Research Scope

• Scope of Analysis

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow?
• The Strategic Imperative 8
• The Impact of the Top 3 Strategic Imperatives on the Biopharma Industry

Growth Opportunity Analysis

• Growth Drivers
• Growth Restraints
• Trend 1: The AI Advantage
• AI Impact on Biopharma: Timeline to 2040
• Trend 2: Precision Medicine
• Pharmacogenomics and Theranostics: Timeline to 2040
• Trend 3: Shifts in Product Portfolio Strategy
• Portfolio Management to Product Engine
• Trend 4: Convergence of Novel Modalities
• Top 20 Biopharma Pipeline Gravity Shifting Towards Biologics and Emerging Modalities
• Converging Modalities to Integrated Product Engines
• Trend 5: Smart Factory Investments
• Manufacturing Transformation: Timeline to 2040
• Trend 6: Regulatory Evolution
• Regulatory Developments: Timeline to 2040
• Trend 7: Supply Chain Transformation
• Supply Chain Transformation: Timeline to 2040
• Trend 8: Emerging Markets
• Emerging Markets Role: Timeline to 2040
• Trend 9: Data and Digital Transformation
• Data Strategy and Digitalization: Timeline to 2040
• Trend 10: Big Tech is Becoming a Co-Orchestrator in Biopharma
• Big Tech Disruption: Timeline to 2040

Growth Opportunity Universe

• Growth Opportunity 1: ADC & Radioligand Supply Ecosystems
• Growth Opportunity 2: Micro-Batch Personalized Therapy Infrastructure
• Growth Opportunity 3: AI-Augmented Clinical Development Platforms
• Growth Opportunity 4: ESG-Differentiated Manufacturing & Green Bioprocessing

Next Steps

• Benefits and Impacts of Growth Opportunities
• Next Steps
• Legal Disclaimer

Author: Anantharaman Viswanathan